Peptide RegisterUK

Home / Already taking it / Ending treatment

Stopping

The most under-discussed fact about this entire class: appetite comes back, and usually so does the weight. What the evidence shows and what a plan looks like.

The short version

The situation

You are thinking about stopping, or you have to, or you have been told it is a course you will finish.

The short answer

These drugs work while you take them. Trial follow-up consistently shows substantial weight regain after stopping, because the appetite suppression ends and the underlying biology has not changed.

The catch

This reframes the whole thing from a course to an ongoing treatment, and it is the single most important question to ask before starting rather than after.

This is a reference, not medical advice. Anything about your own treatment is a conversation with whoever prescribes for you.

01What the evidence shows

Follow-up from trial extensions across this class has generally found that a substantial proportion of lost weight returns within a year or two of stopping. That is consistent across drugs and it is the expected result of removing an appetite suppressant from somebody whose appetite regulation has not otherwise changed.

The liraglutide SCALE extension data was among the earliest evidence of this, and it has been repeated since. It is not a peculiarity of one drug.

Why this matters more than any efficacy figure

A drug that produces twenty per cent weight loss which returns is not obviously better than one producing fourteen per cent that you can keep taking. Access, affordability and tolerability determine whether you can stay on it, which makes them part of the effectiveness question rather than separate from it.

Commentary has argued this class should be described as weight management rather than weight loss, since some people may need to remain on treatment indefinitely. That is a reasonable reading of what the data shows.

02Stopping is a clinical event, not just ceasing

NICE guidance for tirzepatide covers deprescribing and includes advice and support after stopping. That tells you the health service treats this as something needing a plan rather than simply running out.

Reasons people stop are varied and mostly legitimate: side effects, cost, supply, reaching a goal, pregnancy or planning one, or another condition changing the picture. None of them is a failure, and all of them are better handled with the prescriber than around them.

03What a plan can include

Not instructions. Things that exist as options and are worth asking about.

  • A slower reduction rather than a hard stop. Whether this helps is not firmly established, and it is being studied, including work on spacing doses further apart to maintain effect.
  • Support after stopping, which NICE guidance for tirzepatide specifically includes.
  • Keeping the things that were not the drug. Resistance training, protein, sleep and whatever eating patterns you built are yours to keep and are the part that does not stop working.
  • Agreeing what would trigger restarting, in advance, so it is a plan rather than a decision made in a bad week.
  • Being clear on how quickly it clears. A weekly drug persists for a while after the last dose; the effect does not vanish overnight.

04What changes when you stop

Appetite returns, generally over weeks rather than immediately. The side effects also stop, which for people who had a rough time is a genuine relief and is worth saying.

If you have type 2 diabetes, glucose control will change and needs managing. If you were on insulin or a sulfonylurea alongside, doses may need revisiting in the other direction.

And the weight regain, if it happens, is not a moral event. The biology that made weight difficult before has not been altered by having treated it for a while. That is precisely why the regain happens, and precisely why it is not a verdict on you.

05If you are stopping because you cannot afford it

Worth naming directly, because it is one of the most common reasons and rarely gets discussed.

NHS access exists for both semaglutide and tirzepatide under eligibility criteria, and tirzepatide prescribing for obesity entered the GP contract in April 2026 with phased rollout. Whether you qualify depends on criteria and where you live, and it is worth asking your practice directly rather than assuming.

Buying unlicensed product because the licensed version has become unaffordable is the substitution this whole site exists to argue against. The problem it solves is cost. The problem it creates is that you no longer know what you are injecting.

06Questions worth asking

Take these to your GP, practice nurse, pharmacist or specialist team. The answers are specific to you in a way nothing on this page can be.

  1. What is the plan for stopping, and what support is there afterwards?
  2. Is a gradual reduction an option rather than stopping outright?
  3. What would we look for that would mean restarting?
  4. Do my other medicines need adjusting as I come off this?
  5. Am I eligible for NHS funding, if cost is the reason I am stopping?

07Common questions

Will I put the weight back on if I stop Mounjaro or Wegovy?

Most likely some or most of it. Trial follow-up across this class consistently shows substantial regain after stopping, because the appetite suppression ends and the underlying biology has not changed. Planning for that before starting is better than discovering it after.

How long do I have to stay on it?

There is no fixed course. The evidence points towards ongoing treatment for many people, which is why commentary has argued the class should be described as weight management rather than weight loss. It is a question to ask your prescriber early.

Can I taper off instead of stopping suddenly?

It is worth asking about. Whether tapering reduces regain is not firmly established, and research is looking at approaches including spacing doses further apart. NICE guidance for tirzepatide covers deprescribing and post-treatment support.

Is it dangerous to stop suddenly?

There is no withdrawal syndrome in the way that phrase usually implies. For type 2 diabetes, glucose control will worsen and needs managing, so stopping should go through whoever manages your diabetes rather than happening on its own.

08Sources

  1. SCALE trial extension data on weight regainPubMed
  2. STEP trial extension dataPubMed
  3. Tirzepatide guidance including deprescribingNICE
  4. Obesity guidanceNICE
  5. When it slows downOn this site
PreviousWhen you cannot get hold of it